eCite Digital Repository
ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases
Citation
Ding, C and Xu, J and Li, J, ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases, Current Opinion in Investigational Drugs, 9, (5) pp. 515-522. ISSN 1472-4472 (2008) [Refereed Article]
Abstract
ABT-874, a fully human mAb that blocks the binding of IL-12 and IL-23 to their shared IL-12 receptor β1, is currently being developed by Abbott Laboratories for the potential treatment of Crohn's disease and psoriasis. The compound is currently in phase III clinical trials for psoriasis and phase II trials for Crohn's disease. ABT-87 was previously being developed for the potential treatment of multiple sclerosis; however, by May 2007, development for this indication was discontinued. © The Thomson Corporation.
Item Details
| Item Type: | Refereed Article |
|---|---|
| Research Division: | Biomedical and Clinical Sciences |
| Research Group: | Clinical sciences |
| Research Field: | Rheumatology and arthritis |
| Objective Division: | Health |
| Objective Group: | Clinical health |
| Objective Field: | Clinical health not elsewhere classified |
| UTAS Author: | Ding, C (Professor Chang-Hai Ding) |
| ID Code: | 54879 |
| Year Published: | 2008 |
| Web of Science® Times Cited: | 37 |
| Deposited By: | Menzies Institute for Medical Research |
| Deposited On: | 2009-03-02 |
| Last Modified: | 2009-04-25 |
| Downloads: | 0 |
Repository Staff Only: item control page